EarliTec Diagnostics, a medical device company focused on diagnostic and therapeutic solutions for children with autism and related early childhood vulnerabilities, announced today a $21.5 million Series B financing round, led by Nexus NeuroTech Ventures and Venture Investors Health Fund. The funds will be used to expand commercialization efforts and advance clinical research for the first-in-kind EarliPoint™ Evaluation (EarliPoint), which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.

EarliTec Diagnostics is a medical device company making earlier identification and treatment for autism and related early childhood vulnerabilities accessible to children everywhere. Developed by leading researchers at Children's Healthcare of Atlanta, Emory University School of Medicine and Yale University, EarliTec is pioneering the development of biomarkers that help parents and providers understand how a child is looking and learning from the world around them. The underlying technology was developed through extensive research funded by philanthropist Bernie Marcus. The company's initial product, the EarliPoint Evaluation, is the first objective measurement tool that clinicians can use to aid in the diagnosis and assessment of autism in children as young as 16 months. As of today, 12 EarliPoint devices are in 8 centers across 6 states in the U.S.